Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299141 | 0.84 | HSD17B10 (0.37) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL18930241 | 0.84 | HSD17B10 (0.37) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL6757190 | 0.81 | CBFB (0.46) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL18930378 | 0.79 | HSD17B10 (0.41) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL22399096 | 0.77 | PDE2A (0.39) | KDM4EALDH1A1HPGDPARP1RPS6KA3 | |
| SCHEMBL12402507 | 0.75 | HSD17B10 (0.38) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL3269250 | 0.71 | HSD17B10 (0.40) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL4125230 | 0.70 | MGAM (0.50) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL19954109 | 0.70 | KDM4E (0.42) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL19540004 | 0.70 | HSD17B10 (0.45) | HSD17B10KDM4ELMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.